1[1]Skerjance A,Berenson J,Hsu C,et al.The Pharmacokinetics and harnacodynemics of Zoledronic Acid in Cancer Patients with varying Degrees of Renal Function[J].J Clin Pharmacol,2003,43 (2):154-162.
2[2]Croucher P,Jagdev S,Coleman R.The anti-tumor potential of zoledronic acid[J].Breast,2003,12 (2):30-36.
3[3]Body JJ.Clinical research update:Zoledronic[J].Cancer,1997,15 (8):1699-1701.
4[4]Mundy GR,Yoneda T,Hiraga T.Preclinical studies with zoledronic acid and other bisphosphonates:impact on the bone microenvironment[J].Semin oncol.2001,28 (4):35-44.
5[7]Major PP,Coleman RE.Zoledronic acid in treatment of hypercalcemia of malignancy:Results of the international clinical development program[J].Semin oncol,2001,289 (2 Suppl 6):17-19.
6[8]Major P,Lortholary A,Hon J,et al.Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy:a pooled analysis of two randomized,cont rolled clinical t rials[J].J Clin Oncol,2001,19 (2):558-567.
7[9]Reid IR,Brown JR,Burckhard P,et al.Intravenous Zoledronic acid in postmenopausal women with low bone mineral density[J].N Engl J Med,2002,346 (9):653-656.
8[10]Rosen LS,Gordon D Kaminskim,et al.Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma:a phase Ⅲ,double-blind,comparcative trial[J].Cancer J,2001,Sep 31; 7 (5):377-387.
9[11]Rosen LS,Gordon D,Tchek Medyian S,et al.Long-Term efficacy and safety of Zoledronic acid compared with pamidronate disodium in the treatment of skeletal complication in patients with advanced multiple or breast carcinoma:a randomized,double-blind,multicenter,comparative trial[J].Cancer,2003,98 (8):1735-1744.
10[12]Rosen LS,Gordon DH,Dugan W,et al.Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion[J].Cancer,2004,100 (1):36-43.
